

17.

Bölüm

MALİGN PLEVRAL MEZOTELYOMADA RADYOTERAPİ

Hale Başak ÇAĞLAR¹

OLGU

İlk olarak Nisan 2018’de nefes darlığı şikâyeti başlayan hastaya yapılan tetkiklerde sol hemitoraksta plevral kalınlaşma tespit edilmiştir. Hastanın Temmuz 2018 pozitron emisyon tomografisinde (PET-BT) plevrada malign FDG uptake izlenmiştir. Hastaya radikal plevrektomi uygulanmış, aynı seansta hipertermik kemoterapi yapılmıştır. Hastanın postoperatif patoloji sonucu epitelioid mezotelyoma olarak gelmiştir. Bunun üzerine hastaya 6 kür sisplatin ve pemetreksed ve 2 kür idame pemetreksed uygulanmıştır. Hastanın kontrol PET-BT’inde sol hemitoraksta birkaç alanda şüpheli uptake mevcuttur ve eskisine göre belirginleşmiştir. Bunun üzerine hastaya ipsilateral hemitorasik radyoterapi (RT) endikasyonu konulmuştur. Hastaya 54 Gy RT uygulanmıştır. Simultane integre boost tekniği ile nüks bölgesinde doz artımı sağlanmıştır (Resim 1). 7/2019’den sonra alt solunum yolu enfeksiyonu nedeniyle tedavi olan hastanın genel durum daha ortadır. Hastanın 2 ay sonra çekilen kontrol PET-BT’inde (9/2019) yaygın radyasyon pnömonitisi gelişmiştir. Bunun üzerine hastaya radyasyon pnömonitisi tanısıyla tedavi başlanmış ve tedavi ile semptomatik rahatlama olmuştur. Hastanın kontrol takiplerinde akut konsolidasyon azalmış, fibrozis gelişmiş ve tümör progresyonu saptanmamıştır. Hastanın 2 yıllık takiplerinde yeni gelişen bir lezyon izlenmemiştir.

¹ Prof. Dr. Hale Başak ÇAĞLAR, Anadolu Sağlık Merkezi, Radyasyon Onkolojisi Kliniği
halebasakcaglar@gmail.com

KAYNAKLAR

1. Peto J, Decarli A, La Vecchia C, et al.: The European mesothelioma epidemic. *Br J Cancer* 1999;79:666–672.
2. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. *Crit Rev Toxicol* 2009;39:576–588.
3. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. *Cancer* 2006;107:108–115.
4. Takagi A, Hirose A, Nishimura T, et al. Induction of mesothelioma in p53/mouse by intraperitoneal application of multi-wall carbon nanotube. *J Toxicol Sci* 2008;33:105–116.
5. McLaren BR, Haenel T, Stevenson S, et al. Simian virus (SV) 40 like sequences in cell lines and tumor biopsies from Australian malignant mesotheliomas. *Aust N Z J Med* 2000;30:450–456.
6. Gulmez I, Kart L, Buyukoglan H, et al. Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. *Can Respir J* 2004;11:287–290.
7. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. *J Clin Oncol* 2009;27:2081–2090.
8. Ja`nne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. *Thorac Surg Clin* 2004;14:567–573.
9. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. *Ann Surg Oncol* 1997;4:215–222.
10. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 2001;122:788–795.
11. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. *Ann Thorac Surg* 1997;63:334–338.
12. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003;21:2636–2644.
13. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. *Ann Oncol* 2007;18:1196–1202.
14. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. *Ann Surg* 1996;224:288–294.
15. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. *Lung Cancer* 2007;57:89–95.
16. Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in western Australia. *J Thorac Oncol* 2009;4:1010–1016.
17. Batirel HF, Metintas M, Caglar HB, et al. Trimodality treatment of malignant pleural mesothelioma. *J Thorac Oncol* 2008;3:499–504.
18. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. *J Clin Oncol* 2009;27:3007–3013.
19. de Perrot M, Feld R, Cho J, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. *J Clin Oncol* 2009;27:1413–1418.
20. Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. *Eur Respir J* 2010;36:1362–1369.

21. Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. *Ann Thorac Surg* 2009;88:870–876.
22. Okubo K, Sonobe M, Fujinaga T, et al. Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. *Gen Thorac Cardiovasc Surg* 2009;57:585–590.
23. Pagan V, Ceron L, Paccagnella A, et al. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. *J Cardiovasc Surg* 2006;47:595–601.
24. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. *J Thorac Oncol* 2006;1:289–295.
25. Maggi G, Casadio C, Cianci R, et al. Trimodality management of malignant pleural mesothelioma. *Eur J Cardiothorac Surg* 2001;19:346–350.
26. Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. *Int J Radiat Oncol Biol Phys* 2007;68:1366–1374.
27. Gupta V, Krug LM, Laser B, et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. *J Thorac Oncol* 2009;4:746–750.
28. Ahamad A, Stevens CW, Smythe WR, et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys*. 2003 Mar 1;55(3):768–75.
29. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. *Ann Thorac Surg* 2007;84:1685–1693.
30. van Sandick JW, Kappers I, Baas P, et al. Surgical treatment in the management of malignant pleural mesothelioma: a single institution's experience. *Ann Surg Oncol* 2008;15:1757–1764.
31. Miles EF, Larrier NA, Kelsey CR, et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. *Int J Radiat Oncol Biol Phys* 2008;71:1143–1150.
32. Tonoli S, Vitali P, Scotti V, et al. Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series *Radiother Oncol*. 2011 Nov;101(2):311–5.
33. Krayenbuehl J, Dimmerling P, Ciernik IF, et al. Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma. *Radiat Oncol*. 2014 Jan 24;9:32.
34. Patel PR, Yoo S, Broadwater G, et al. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2012 May 1;83(1):362–8.
35. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys* 2007;69:350–357.
36. Allen AM, Czerninska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. *Int J Radiat Oncol Biol Phys* 2006;65:640–645.
37. Kristensen CA, Nøttrup TJ, Berthelsen AK, et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. *Radiother Oncol* 2009;92:96–99.
38. Allen AM, Schofield D, Hacker F, et al. Restricted field IMRT dramatically enhances IMRT planning for mesothelioma. *Int J Radiat Oncol Biol Phys* 2007;69:1587–1592.
39. Zhu XR, Prado K, Liu HH, Guerrero TM, et al. Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency. *Int J Radiat Oncol Biol Phys* 2005;62:1525–1534.
40. Jang SY, Liu HH, Wang X, et al. Underestimation of low-dose radiation in treatment planning of intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys* 2008;71:1537–1546.

41. Court LE, Ching D, Schofield D, et al. Evaluation of the dose calculation accuracy in intensity-modulated radiation therapy for mesothelioma, focusing on low doses to the contralateral lung. *J Appl Clin Med Phys* 2009;10:34–42.
42. Fenwick JD, Tome' WA, Soisson ET, et al. Tomotherapy and other innovative IMRT delivery systems. *Semin Radiat Oncol* 2006;16:199–208.
43. Sterzing F, Sroka-Perez G, Schubert K, et al. Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step-and-shoot IMRT. *Radiother Oncol* 2008;86:251–257.
44. Scorsetti M1, Bignardi M, Clivio A, et al. Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study. *Int J Radiat Oncol Biol Phys*. 2010 Jul 1;77(3):942-9.
45. Suit H, Urie M. Proton beams in radiation therapy. *J Natl Cancer Inst* 1992;84:155–164.
46. Kravenbuehl J1, Hartmann M, Lomax AJ, et al. Proton therapy for malignant pleural mesothelioma after extrapleural pneumonectomy. *Int J Radiat Oncol Biol Phys*. 2010 Oct 1;78(2):628-34.
47. Lorentini S, Amichetti M, Spiazzi L, et al. Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment. *Strahlenther Onkol*. 2012 Mar;188(3):216-25.
48. Burt BM, Cameron RB, Mollberg NM, et al. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. *J Thorac Cardiovasc Surg*. 2014 Jul;148(1):30-5.
49. Sugarbaker DJ, Wolf AS, Chirieac LR, et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. *Eur J Cardiothorac Surg*. 2011 Aug;40(2):298-303.
50. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic features in the treatment of malignant pleural mesothelioma at a large tertiary referral center. *J Thorac Oncol* 2007; 2: 957–65.
51. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. *J Thoracic Cardiovasc Surg* 2008; 135: 620–26.
52. Burt BM, Cameron RB, Mollberg NM, et al. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. *J Thorac Cardiovasc Surg*. 2014 Jul;148(1):30-5.
53. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys*. 2005 Nov 15;63(4):1045-52.
54. Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys*. 2012 Jul 15;83(4):1278-83.
55. Minatel E, Trovo M, Polesel J, et al. Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung. *J Thorac Oncol*. 2012 Dec;7(12):1862-6.
56. Chance WW, Rice DC, Allen PK, et al. Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis. *Int J Radiat Oncol Biol Phys* 2015 Jan 1;91(1) 149-156.
57. Rimner A, Spratt DE, Zauderer MG, et al. Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys*. 2014 Oct 1;90(2):394-401.
58. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. *Chest* 108, 754–758 (1995).
59. Bydder S, Phillips M, Joseph DJ et al. A randomised trial of single-dose radiotherapy to pre-

- vent procedure tract metastasis by malignant mesothelioma. *Br. J. Cancer* 91, 9–10 (2004).
60. O'Rourke N, Garcia JC, Paul J et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. *Radiother. Oncol.* 84, 18–22 (2007).
 61. Ung YC, Yu E, Falkson C et al. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. *Radiother. Oncol.* 80, 3–8 (2006).
 62. McAleer MF, Tsao AS, Liao Z. Radiotherapy In Malignant Pleural Mesothelioma. *Int J Radiat Oncol Biol Phys.* 2009 Oct 1;75(2):326-37.
 63. Clive AO, Wilson P, Taylor H, et al. Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases. *BMJ Open.* 2015 Jan 9;5(1):e006673.
 64. van Thiel ER, Surmont VF, van Meerbeeck JP. Malignant pleural mesothelioma: when is radiation therapy indicated? *Expert Rev Anticancer Ther.* 2011 Apr;11(4):551-60.
 65. Gordon W, Antman KH, Greenberger JS et al. Radiation therapy in the management of patients with mesothelioma. *Int. J. Radiat. Oncol. Biol. Phys.* 8, 19–25 (1982).
 66. Macleod N, Price A, O'Rourke N, et al. Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review. *Lung Cancer.* 2014 Feb;83(2):133-8.